GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD
GH Research PLC announced the peer-reviewed publication of its Phase 2b clinical trial results for GH001 (mebufotenin) in treatment-resistant depression (TRD) in JAMA Psychiatry. The study demonstrated significant efficacy and safety of GH001, with remission rates independent of the number of prior antidepressant treatment failures, a notable break…